Scientists uncover structural biology details of SARS-CoV-2 infection
Researchers have used computer simulations to model how the SARS-CoV-2 fusion peptide interacts with and penetrates the cell membrane.
List view / Grid view
Researchers have used computer simulations to model how the SARS-CoV-2 fusion peptide interacts with and penetrates the cell membrane.
Researchers have developed stem cell-derived organoids to reveal how SARS-CoV-2 interacts with lung and brain cells differently.
Between January and October 2020, scientists globally have published more than 87,000 papers about the coronavirus.
Vascor (bepridil) could be used to treat COVID-19, according to a new study which screened drugs to repurpose against SARS-CoV-2.
Researchers have found that the S1/S2 cleavage of the SARS-CoV-2 Spike protein could be a potential target for COVID-19 therapeutics.
The UK Government will give £18.5 million in funding to four studies researching the causes and potential treatments of long COVID.
A study has shown the D614G mutation in the Spike protein of SARS-CoV-2 makes the coronavirus more transmissible than the original virus from China.
A peptide administered to ferrets protected them from SARS-CoV-2 viral transmission when housed with infected ferrets.
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
A study has shown that targeting the protein Nsp1 can inhibit genes for viral replication, which could lead to new COVID-19 treatments.
Comparing the original SARS-CoV-2 Spike protein with a mutated version, researchers have potentially revealed why the mutated version is dominant.
A team has developed a machine learning approach to screen for and identify drugs that could be repurposed against COVID-19 in the elderly.
Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
Research has shown that ACE2 and several integrins containing SLiMs are involved in SARS-CoV-2 infection, presenting new therapeutic targets.
Researchers studying SARS-CoV-2 at the individual cellular level have made four major discoveries about early infection from the coronavirus.